Ozempic vs Wegovy vs Mounjaro: A Doctor's Comparison for Indians (2026)

Editorial notice: This article is general educational content about prescription weight-management treatments available in India. It is not medical advice, not a recommendation to use any specific medication, and not a promotion of any brand. NuvaHealth does not sell, stock, or dispense any medication. All treatment decisions must be made in a private consultation with a qualified doctor who has reviewed your complete medical history. Prescription medicines discussed here are Schedule H drugs and are available only with a valid prescription from a licensed pharmacy.

The Three Names Everyone Is Confusing

Ozempic, Wegovy and Mounjaro are the three names dominating every conversation about weight-loss medication in India. They are mentioned almost interchangeably on social media, in WhatsApp groups and across pharmacy apps — as if they were three versions of the same thing. They are not.

The confusion is understandable, but it matters, because these medications differ in the molecule they contain, what they are officially approved to treat, how much weight they produce in trials and what they cost. Choosing between them is a medical decision — but understanding the difference is something every patient should do before that conversation with a doctor.

Here is the single most useful fact to start with: there are only two drug molecules involved — semaglutide and tirzepatide. Everything else is a brand name.

Ozempic vs Wegovy: The Same Molecule, a Different Job

Both Ozempic and Wegovy contain the same active molecule: semaglutide, a once-weekly GLP-1 receptor agonist made by Novo Nordisk. The difference is the dose and the official purpose.

• Ozempic is approved for type 2 diabetes, with a maximum dose of 2 mg per week. In India it is widely prescribed off-label for weight loss — meaning a doctor prescribes it for a purpose other than its official approval, which is legal and common but should always be a doctor's decision.
• Wegovy is approved specifically for chronic weight management. It is the same semaglutide, but at a higher maximum dose of 2.4 mg per week — the dose used in the major weight-loss trials. Wegovy launched in India in 2025.

So if someone asks whether to use Ozempic or Wegovy for weight loss, the honest answer is that Wegovy is the version actually designed and dosed for the job. Ozempic became famous first only because it reached the market earlier. Rybelsus, a third Novo Nordisk brand, is oral semaglutide in tablet form, approved for diabetes — useful to know if injections are a concern, though the weight-loss evidence for the tablet is more limited.

Mounjaro: The Dual-Action Newcomer

Mounjaro contains a different, newer molecule: tirzepatide, made by Eli Lilly. What makes it different is that it is a dual agonist — it activates two gut-hormone receptors, GIP and GLP-1, rather than just one.

In simple terms, semaglutide pulls one biological lever to reduce appetite; tirzepatide pulls two. Mounjaro launched in India in March 2025 and is approved for both type 2 diabetes and chronic weight management. The United States uses a separate brand, Zepbound, for the weight-loss indication; that brand is not in India.

How Do They Compare on Weight Loss?

This is where the numbers become genuinely useful. In the large clinical trials:

• Semaglutide 2.4 mg (Wegovy) — average weight loss of about 14.9% of body weight over 68 weeks, in the STEP-1 trial.
• Tirzepatide 15 mg (Mounjaro) — average weight loss of about 21% of body weight over 72 weeks, in the SURMOUNT-1 trial.

The two were also compared directly. In the SURMOUNT-5 head-to-head trial, tirzepatide produced roughly 20.2% weight loss versus 13.7% for semaglutide — close to 50% more weight loss in that study.

It is tempting to read this as a simple win for Mounjaro. But two cautions matter. First, both drugs vastly outperform any diet or supplement — the gap between them is far smaller than the gap between either drug and lifestyle change alone. Second, trial averages are not individual promises: some people respond better to one molecule than the other, and tolerability differs from person to person.

Are the Side Effects Different?

The side-effect profiles are broadly similar, because both molecules work on the same GLP-1 pathway. The most common effects are gastrointestinal — nausea, constipation, diarrhoea and reduced appetite — and they are usually mild to moderate and worst in the early weeks as the dose is increased.

Both carry the same more-serious considerations: a small risk of pancreatitis and gallbladder problems, and a warning against use by anyone with a personal or family history of medullary thyroid cancer. Both can also cause loss of muscle alongside fat, which is why supervision and adequate protein matter. We cover all of this in our guide to GLP-1 side effects and how to manage them.

What Each One Costs in India

Cost is often the deciding practical factor. Approximate Indian prices in 2026:

• Mounjaro — roughly Rs 13,000 to Rs 26,000 per month depending on the dose, available as both vials and pre-filled KwikPens.
• Wegovy — broadly in a similar monthly range, varying by dose and supplier.
• Ozempic and Rybelsus — priced for the diabetes market; cost varies by pharmacy and dose.

Prices change, and because the dose is escalated gradually, the early months often cost less than later ones. Crucially, never buy these medications from unverified online sellers or grey-market sources — counterfeit GLP-1 products are a documented and dangerous problem. These are Schedule H prescription drugs for a reason.

So Which One Is the Best?

There is no single best medication — there is only the best fit for a specific person. The right choice depends on factors a doctor weighs together:

1. Your medical history — diabetes status, thyroid history, pancreatitis history, other conditions.
2. Your weight-loss target and starting point.
3. How well you tolerate the medication — which often only becomes clear after starting.
4. Cost and what you can sustain — these are long-term treatments, not one-month courses.
5. Availability of the specific brand and dose.

A more powerful drug on paper is not automatically the right drug for you, if a lower dose of another achieves your goal with fewer side effects.

The Decision Is Medical — Make It With a Doctor

Comparing Ozempic, Wegovy and Mounjaro is genuinely useful — it turns a confusing set of names into an informed starting point. But the comparison ends where the prescription begins. These medications interact with your other conditions and medicines, require dose adjustment and monitoring, and work properly only as part of a supervised plan that includes nutrition and muscle preservation. For the wider picture of why medication works where willpower alone often does not, see our guide on why diets fail.

Discuss Your Options With a Doctor on NuvaHealth

NuvaHealth connects you with licensed Indian doctors who can review your full medical history and help you understand whether medication has any role in your weight management — and if so, which approach fits you. Private video consultation from home, evidence-based and unhurried.

Start your assessment on NuvaHealth today and get a clear, personalised answer instead of social-media guesswork.